Yale AI Uses ECG Images to Flag Risk of Cardiac Amyloidosis
Published in Artificial Intelligence, Personalized medicine, Tools.
Yale School of Medicine reported on September 25, 2026 that its researchers developed an AI platform to flag people at risk of transthyretin amyloid cardiomyopathy using images of electrocardiograms. The condition involves abnormal protein deposits that can damage the heart and is often diagnosed late.
The smartphone-accessible approach analyzes ECG images rather than requiring a new specialized imaging examination. Yale says the research team evaluated the model in eight patient cohorts across the United States and Europe. Its proposed role is to identify people who should receive further evaluation, rather than provide a definitive diagnosis from an ECG alone.
According to the announcement, the tool received FDA Breakthrough Device designation and was under FDA review. That designation is not marketing authorization. Yale also described the TRACE-AI Network Study, an observational implementation study at 13 health centres.
The work points toward more accessible screening, but the announcement does not demonstrate that deployment improves survival or other patient outcomes.
Source: Yale School of Medicine, September 25, 2026. Regulatory status is reported as described in that announcement.